APA (7th ed.) Citation

Saadany, T. E., Lupatsch, J., Mark, M., Barbier, M., Mehra, T., Schwenkglenks, M., & Moos, R. v. A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. SMW supporting association (Trägerverein Swiss Medical Weekly SMW).

Chicago Style (17th ed.) Citation

Saadany, Tämer El, Judith Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, and Roger von Moos. A Cost-effectiveness Analysis of Sotorasib as Second-line Treatment for Patients with KRAS-G12C-mutated Metastatic Non-small Cell Lung Cancer (mNSCLC) in Switzerland. SMW supporting association (Trägerverein Swiss Medical Weekly SMW).

MLA (9th ed.) Citation

Saadany, Tämer El, et al. A Cost-effectiveness Analysis of Sotorasib as Second-line Treatment for Patients with KRAS-G12C-mutated Metastatic Non-small Cell Lung Cancer (mNSCLC) in Switzerland. SMW supporting association (Trägerverein Swiss Medical Weekly SMW).